Antiplatelet agents for the treatment and prevention of coronary atherothrombosis

Journal article

Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures.

Authors: Patrono, C; Morais, J; Baigent, C; Collet, J; Fitzgerald, D

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier
• Journal: Journal of the American College of Cardiology
• Volume: 70
• Issue: 14
• Pages: 1760-1776
• Publication date: 2017-09-25
• Acceptance date: 2017-08-09
• DOI: 10.1016/j.jacc.2017.08.037
• EISSN: 1558-3597
• ISSN: 0735-1097
• Pmid: 28958334
• Language: English
• Keywords: coronary artery disease; risk assessment; vorapaxar; ticagrelor; aspirin; clopidogrel; platelet aggregation inhibitors; cangrelor; prasugrel